Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 2Waldenstrom Macroglobulinemia 1Solitary Fibrous Tumor, Pleural 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Cancer Pain 1Breast Neoplasms 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1Adult Patients Who Are Receiving Oncologic Care 1Adjustment Disorders 1

Interventions

Rituximab 53Cyclophosphamide 50Lenalidomide 41fludarabine 24obinutuzumab 23Prednisone 19Bendamustine Hydrochloride 19Magnetic Resonance Spectroscopy 18Vincristine 17Doxorubicin 16fludarabine phosphate 15Specimen Handling 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tafasitamab 4polatuzumab vedotin 4acalabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Pharmacogenomic Testing × 1 year × Clear all
NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
48 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡